For Online Payment

ATOPIC DERMATITIS

Abstract

Atopic dermatitis (AD), also known as atopic eczema, is a common chronic inflammatory skin condition characterized by itching, redness, scaling, dryness, crusting, fissuring and lichenification. It affects approximately 13% of children and 5% of adults.

AD develops through a complex interaction of genetic predisposition, impaired skin-barrier function, immune dysregulation, neuroinflammation, changes in the skin microbiome and environmental factors. Many patients also have an atopic background, such as a personal or family history of asthma, allergic rhinitis, conjunctivitis or atopic dermatitis.

Management depends on disease severity and may include regular moisturization and skin-barrier care, topical anti-inflammatory treatments, phototherapy, systemic immunosuppressive medicines, biologic therapies and oral JAK inhibitors. Identifying individual triggers and associated allergic conditions can also be important.

With newer targeted treatments, particularly biologic agents and JAK inhibitors, treatment of moderate-to-severe AD is becoming increasingly individualized.


What Is Atopic Dermatitis?

Atopic dermatitis is a chronic, relapsing inflammatory skin disease that can occur at any age but most commonly begins during childhood.

The condition is associated with abnormalities in the skin barrier and immune system. When the skin barrier is weakened, irritants, allergens and microorganisms can penetrate the skin more easily. This can contribute to inflammation, itching and recurrent flare-ups.

AD is also frequently associated with other allergic conditions, including:

  • Allergic asthma
  • Allergic rhinitis
  • Allergic conjunctivitis
  • Food allergy

The condition can also occur alongside other non-atopic problems, including psychological and psychosomatic disorders.


Common Symptoms and Clinical Features

The appearance of atopic dermatitis varies according to age, disease stage and chronicity.

Common symptoms include:

  • Intense itching
  • Dry skin or xerosis
  • Redness and inflammation
  • Scaling
  • Oozing and crusting
  • Skin fissures
  • Excoriation caused by scratching
  • Lichenification or thickening of the skin
  • Recurrent flare-ups

In Infants

Atopic dermatitis may appear during the first few months of life. Commonly affected areas include:

  • Cheeks
  • Head
  • Scalp
  • Trunk
  • Extensor surfaces of the limbs

Early lesions may appear as red, oozing and crusted plaques, particularly on the cheeks.


In Older Children and Adults

With increasing age, involvement of the flexural areas becomes more prominent. Other presentations may involve the head, face, neck, upper chest and back.

Different clinical patterns may include:

  • Flexural type
  • Extensor surface type
  • Dry form in childhood
  • Head, face and neck type
  • Prurigo type
  • Erythrodermic type

A characteristic headlight sign, involving centrofacial pallor with sparing around the nose and paranasal area, may also be seen.


The Itch-Scratch Cycle

One of the most important features of atopic dermatitis is persistent itching.

Itching leads to scratching, and repeated scratching damages the already weakened skin barrier. This further increases inflammation and can stimulate the release of itch-associated mediators such as IL-31, IL-33 and TSLP.

This creates a continuous cycle:

Skin inflammation → Itching → Scratching → Barrier damage → Increased inflammation → More itching

Breaking this itch-scratch cycle is therefore an important part of controlling atopic dermatitis.


What Triggers Atopic Dermatitis?

AD is influenced by multiple environmental and individual factors. Commonly discussed triggers include:


1. Food Allergen Sensitization

Food sensitization and AD can have a complex relationship. Food sensitization may occur through the skin when the epidermal barrier is impaired.

Food allergy can involve:

  • IgE-mediated reactions
  • Non-IgE-mediated reactions
  • Mixed mechanisms

Food sensitization may be investigated using skin-prick testing or blood tests for specific IgE, including testing against whole allergens or specific allergen components when appropriate.

Food elimination should not be undertaken routinely without appropriate medical assessment.

 

2. Changes in the Skin Microbiome

The skin normally contains a diverse community of microorganisms that contributes to skin health.

In atopic dermatitis, this microbial balance can change, with increased colonization by Staphylococcus aureus.

At the same time, beneficial organisms such as Staphylococcus epidermidis may help limit S. aureus overgrowth.

Changes in the skin barrier, pH and antimicrobial defenses can therefore contribute to inflammation and infection.


3. Pollutants and Chemical Exposure

Environmental pollutants can aggravate AD through mechanisms involving:

  • Oxidative stress
  • Skin-barrier disruption
  • Activation of inflammatory pathways
  • Increased inflammatory cytokine production

Exposure to substances such as cigarette smoke, nitrogen dioxide and indoor pollutants may also influence disease severity.


4. Occupational Triggers

Certain occupations involve repeated exposure to irritants or sensitizing substances and may increase the risk of eczema, particularly hand eczema.

Examples include:

Hairdressers: hair dyes, bleaching agents, detergents and cosmetic products.

Beauticians: acrylics, acrylates, preservatives and wet work.

Healthcare workers: latex, disinfectants, medications and repeated hand washing.

Bakers: flour and grain dust, rubber materials and wet work.

Construction workers: cement, concrete, paints, adhesives, resins and metals.

Agricultural workers: plants, animal materials, disinfectants and rubber materials.

Mechanics and metal workers: cutting fluids, coolants, detergents, metals and petroleum products.

Recognizing occupational exposure can be important when eczema repeatedly affects the hands or worsens during work.


5. Physiochemical Stimuli

Exercise, bathing, increased skin temperature and changes in sweating can influence AD symptoms.

Patients may experience increased water loss through the skin, known as transepidermal water loss (TEWL), following certain physiochemical stimuli.


6. Stress and Psychosomatic Factors

Atopic dermatitis can significantly affect sleep, emotional well-being and daily activities.

Persistent nighttime itching may contribute to sleep disturbance and psychological stress. AD has also been associated with increased rates of anxiety and depression.

Managing stress and addressing sleep problems can therefore form an important part of comprehensive care.


How Is Atopic Dermatitis Diagnosed?

Diagnosis is primarily clinical, based on the patient’s symptoms, skin findings, distribution of lesions, chronicity and associated history.

Important diagnostic features include:


Typical Skin Morphology

Acute lesions may include:

  • Erythema
  • Papules
  • Vesiculopapules
  • Exudation
  • Scaling
  • Crusting

Chronic lesions may show:

  • Thickened skin
  • Lichenification
  • Prurigo
  • Scaling
  • Crusting

 

Typical Distribution

The distribution of lesions changes with age and may involve:

  • Face
  • Forehead
  • Periorbital region
  • Perioral region
  • Neck
  • Trunk
  • Flexural areas
  • Extensor surfaces

Pruritus

Persistent or recurrent itching is a key clinical feature.


Age of Onset

Both early-onset and later-onset forms of AD can occur.


Severity Assessment

Assessing disease severity helps determine the appropriate treatment strategy.

Common assessment tools include:


Eczema Area and Severity Index (EASI)

The EASI score combines the extent of skin involvement with the intensity of lesions across four body regions:

  • Head and neck
  • Upper extremities
  • Trunk
  • Lower extremities

The final score ranges from 0 to 72.

Broadly:

  • 0: Clear/no eczema
  • 0.1–1: Almost clear
  • 1.1–7: Mild
  • 7.1–21: Moderate
  • 21.1–50: Severe
  • >50: Very severe


SCORAD

The SCORing Atopic Dermatitis (SCORAD) index is another commonly used measure of disease severity.

It considers:

  • Extent of disease
  • Intensity of skin lesions
  • Itching
  • Sleep disturbance

The total score ranges from 0 to 103.

The source content classifies:

  • SCORAD <25: Mild
  • SCORAD 25–50: Moderate
  • SCORAD >50: Severe

These scoring systems can also help clinicians monitor changes over time.


Biomarkers in Atopic Dermatitis

Several laboratory markers may provide additional information about disease activity or atopic status.

These include:


Total IgE

Elevated total IgE may reflect an atopic tendency and increased Th2 activity.


Specific IgE

Specific IgE testing can identify sensitization to individual allergens. However, sensitization alone does not necessarily establish clinical allergy; results should be interpreted alongside the patient’s clinical history.


Eosinophil Count

An increased peripheral eosinophil count can be associated with disease activity.


Serum LDH

Serum lactate dehydrogenase (LDH) may reflect disease progression in some patients.


TARC

Thymus and activation-regulated chemokine (TARC) is associated with Th2-driven inflammation and may reflect disease activity.


SCCA2

Serum squamous cell carcinoma antigen 2 (SCCA2) has also been investigated as a marker associated with AD disease activity.


Conditions That Can Resemble Atopic Dermatitis

Several other skin conditions may resemble AD and should be considered during diagnosis.

These include:

  • Contact dermatitis
  • Seborrheic dermatitis
  • Hand dermatitis
  • Psoriasis
  • Prurigo simplex
  • Scabies
  • Miliaria
  • Ichthyosis
  • Xerotic eczema
  • Cutaneous lymphoma
  • Certain immunodeficiency disorders
  • Connective tissue diseases
  • Netherton syndrome

A careful clinical examination helps distinguish these conditions and identify patients who may require additional testing.


Understanding the Skin Barrier

One of the central features of atopic dermatitis is skin-barrier dysfunction.

The outer layer of the skin contains structural proteins, lipids and other components that help prevent excessive water loss and protect against external substances.

Important components include:

  • Ceramides
  • Cholesterol
  • Free fatty acids
  • Filaggrin
  • Tight junction proteins

When the barrier is compromised, allergens, irritants and microorganisms can enter the skin more easily.


The Role of Filaggrin

Filaggrin (FLG) is an important protein involved in maintaining the structure and integrity of the skin barrier.

Filaggrin helps organize keratin fibers within skin cells and contributes to the formation of a healthy outer skin layer.

Filaggrin deficiency or mutations can increase skin permeability. This may facilitate penetration of allergens and contribute to inflammation and sensitization.

The interaction between genetic predisposition, barrier dysfunction and immune activation is therefore an important part of AD pathogenesis.


Immune Mechanisms in Atopic Dermatitis

The immune response in AD is complex.

Type 2 inflammation involving cytokines such as:

  • IL-4
  • IL-5
  • IL-13

plays an important role.

Other immune pathways, including Th22, Th17 and Th1, can also contribute depending on the patient’s age and disease characteristics.

Keratinocytes produce inflammatory mediators and alarmins such as:

  • TSLP
  • IL-33
  • IL-25

These signals can promote type 2 immune responses and contribute to inflammation.

The complex interaction between the skin barrier and immune system explains why AD can vary considerably between individuals.


Management of Atopic Dermatitis

The main goals of treatment are to:

  • Reduce inflammation
  • Control itching
  • Restore the skin barrier
  • Prevent flare-ups
  • Maintain long-term disease control
  • Improve quality of life

Treatment should be individualized according to disease severity, age, affected body areas, associated conditions and previous treatment response.


1. Basic Skin Care

Regular skin care is the foundation of AD management.


Moisturizers and Emollients

Patients should regularly use fragrance-free moisturizers, particularly thicker creams or ointments, to maintain hydration and support the skin barrier.


Bathing

Recommended approaches include:

  • Using lukewarm rather than very hot water
  • Using gentle, non-irritating cleansers
  • Limiting prolonged bathing
  • Applying moisturizer soon after bathing

Trigger avoidance and appropriate skin care should continue even when the skin appears improved.


2. Topical Treatments

Topical anti-inflammatory treatments are generally used for mild disease and as part of treatment for more severe disease.


Topical Corticosteroids

Topical corticosteroids are commonly used as first-line anti-inflammatory therapy.

They help reduce:

  • Inflammation
  • Redness
  • Itching
  • Active eczema

The potency and duration should be selected according to the patient’s age, body site and severity of disease.

Lower-potency corticosteroids are generally preferred for sensitive areas such as the face and neck, while stronger preparations may be used for thicker or more resistant lesions under appropriate medical guidance.

Prolonged inappropriate use of potent topical corticosteroids can increase the risk of adverse effects such as skin thinning and striae.


Topical Calcineurin Inhibitors

The main topical calcineurin inhibitors are:

  • Tacrolimus
  • Pimecrolimus

They reduce T-cell activation and the production of inflammatory cytokines.

They are particularly useful for areas where prolonged corticosteroid use may be undesirable, including the face and skin folds.

They can also be used as intermittent or proactive treatment to reduce recurrent flares.


Other Topical Treatments

The source content also discusses newer topical therapies, including:

  • Delgocitinib
  • Difamilast
  • Crisaborole
  • Topical ruxolitinib
  • Topical roflumilast
  • Tapinarof

These therapies target different inflammatory pathways and may provide non-steroidal or targeted treatment options depending on availability, indication and patient characteristics.


3. Adjuvant Treatments

Additional treatments may be considered depending on the patient’s symptoms and disease characteristics.


Antihistamines

Antihistamines may help selected patients, particularly when itching interferes with sleep. Their use should be individualized.


Phototherapy

Phototherapy can suppress inflammatory immune responses in the skin.

Treatment options discussed include:

  • UVA1
  • Narrowband UVB

 

Antifungal Treatment

When fungal or Malassezia-associated infection is identified, appropriate topical or systemic antifungal treatment may be considered.

 

Probiotics and Vitamin D

The source content discusses evidence regarding probiotics and vitamin D, although their role in preventing or treating AD remains an area of ongoing investigation.


4. Biologic Treatments

Biologic therapies have become important treatment options for patients with moderate-to-severe atopic dermatitis who require systemic therapy.


Dupilumab

Dupilumab is a monoclonal antibody that targets the IL-4 receptor alpha (IL-4Rα) and inhibits signaling from IL-4 and IL-13.

It can reduce skin inflammation and improve the symptoms of AD.

A major advantage is that routine laboratory monitoring is generally not required in the same way as with several conventional systemic immunosuppressive therapies.

Possible adverse effects include:

  • Conjunctivitis
  • Blepharitis
  • Ocular itching
  • Injection-site reactions
  • Head and neck dermatitis

Nemolizumab

Nemolizumab targets the IL-31 receptor alpha (IL-31Rα).

IL-31 is strongly associated with the itch pathway in AD. By blocking IL-31 signaling, nemolizumab is particularly relevant to patients with significant persistent pruritus.


Tralokinumab

Tralokinumab is a monoclonal antibody targeting IL-13.

It inhibits IL-13 signaling and provides another targeted treatment option for appropriate patients with moderate-to-severe AD.


5. Oral JAK Inhibitors

The JAK-STAT pathway plays an important role in signaling several inflammatory cytokines.

JAK inhibitors target intracellular signaling rather than a single cytokine and therefore can influence multiple inflammatory pathways.

Oral JAK inhibitors discussed in the source include:

  • Baricitinib
  • Upadacitinib
  • Abrocitinib

These medications can provide rapid improvement in inflammation and itching in appropriate patients.

However, JAK inhibitors require careful patient selection and appropriate screening and monitoring because of their potential risks.

Depending on the medication and patient, monitoring may include assessment for:

  • Infections
  • Tuberculosis
  • Hepatitis B
  • Blood counts
  • Liver function
  • Kidney function
  • Lipid levels

The potential benefits and risks should be discussed with the treating clinician before treatment.


6. Conventional Immunosuppressive Treatments

For patients with severe disease who require systemic therapy, conventional immunosuppressive agents may also be considered.


Cyclosporine

Cyclosporine is an immunosuppressive medicine that can be used in severe AD.

Because of potential adverse effects involving the kidneys and blood pressure, appropriate monitoring is required.


Methotrexate

Methotrexate may be considered in selected patients, particularly when other associated inflammatory or autoimmune conditions are present. However, the source content notes limited certainty regarding its use specifically for AD.

It is contraindicated during pregnancy and requires appropriate precautions in patients planning conception.


Mycophenolate Mofetil

Mycophenolate may be considered in selected refractory cases, particularly when other systemic options cannot be used.

It is also contraindicated during pregnancy.


Oral Corticosteroids

Systemic corticosteroids may sometimes be used for short-term control of severe acute exacerbations, but long-term use is generally not recommended because of the risk of significant systemic adverse effects and lack of sustained disease control.



7. Allergen Immunotherapy

Allergen-specific immunotherapy may be considered as an additional treatment option in selected patients with moderate-to-severe AD, particularly when the patient also has allergic rhinitis or allergic asthma and a clinically relevant allergen relationship has been established.

The source content describes studies involving both:

  • Subcutaneous immunotherapy (SCIT)
  • Sublingual immunotherapy (SLIT)

Research has included house-dust-mite allergens and other inhalant allergens such as pollens.

The potential role of immunotherapy in modifying the course of AD remains an area of clinical interest.



8. Alitretinoin

Alitretinoin is a retinoid that acts on both retinoic acid and retinoid X receptors.

It has anti-inflammatory and antiproliferative effects and is discussed in the source particularly for severe chronic hand eczema that responds inadequately to topical therapy.

Because it is teratogenic, appropriate pregnancy prevention and laboratory monitoring are essential.


A Personalized Approach to Atopic Dermatitis

There is no single treatment that works equally well for every patient with AD.

Treatment decisions should consider:

  • Age
  • Disease severity
  • Extent of skin involvement
  • Location of lesions
  • Frequency of flares
  • Degree of itching
  • Sleep disturbance
  • Allergic conditions
  • Occupational exposures
  • Response to previous treatment
  • Patient preferences
  • Potential treatment risks

For mild disease, appropriate skin care and topical therapy may be sufficient.

For moderate-to-severe disease that remains uncontrolled despite optimized topical treatment, systemic therapies such as biologics or JAK inhibitors may be considered.


Key Takeaways

  • Atopic dermatitis is a chronic, relapsing inflammatory skin disease involving both skin-barrier dysfunction and immune dysregulation.
  • It commonly begins during childhood but can occur at any age.
  • Itching is a central symptom and contributes to the itch-scratch cycle.
  • Genetic factors, filaggrin deficiency, environmental exposures, allergens and changes in the skin microbiome can all contribute to disease.
  • Food sensitization may be relevant in selected patients but should be assessed carefully rather than assuming that every food is a trigger.
  • Disease severity can be assessed using tools such as EASI and SCORAD.
  • Regular moisturization and skin-barrier care are fundamental to long-term management.
  • Topical corticosteroids and topical calcineurin inhibitors remain important treatments for inflammatory flares.
  • Biologic therapies targeting pathways such as IL-4, IL-13 and IL-31 have expanded treatment options for moderate-to-severe disease.
  • Oral JAK inhibitors provide additional systemic options but require careful screening and monitoring.
  • Treatment should be individualized according to disease severity, patient characteristics and treatment response.

 

When Should You See an Allergy or Dermatology Specialist?

Medical evaluation is particularly important when:

  • Eczema is persistent or repeatedly returns
  • Symptoms interfere with sleep or daily activities
  • The disease is not controlled with appropriate topical treatment
  • There are recurrent skin infections
  • Food allergy is suspected
  • Occupational exposure appears to trigger symptoms
  • The condition is extensive or severe
  • Systemic treatment may be required
  • The diagnosis is uncertain

A specialist assessment can help identify triggers, assess disease severity and develop an individualized treatment plan.

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest Posts

Get Exclusive Discounts and More!

Join Our Newsletter

Sign up for our newsletter to stay updated on our latest pool cleaning and maintenance services. As a subscriber, you’ll receive exclusive discounts, special offers. Enter your email below to join our community!

Specialised allergy care focused on accurate diagnosis, personalised treatment and better quality of life.

Address :